APLS

Q: What is the price of Apellis Pharmaceuticals (APLS) today?

The price of Apellis Pharmaceuticals (APLS) today is $ 40.41, with return of 102.35% compared to the last year. The price of Apellis Pharmaceuticals (APLS) started the year trading around $ 25.12 and today it is at $ 40.41. Follow the real-time price chart, the historical price of Apellis Pharmaceuticals (APLS) and international markets.

Q: When does Apellis Pharmaceuticals (APLS) pay dividends?

Apellis Pharmaceuticals (APLS) did not distribute dividends in the last year.

Q: Is Apellis Pharmaceuticals (APLS) worth it?

Currently, Apellis Pharmaceuticals (APLS) is priced at $ 40.41, with a P/E of 229.11%, representing a deviation of 4,662% from its historical average P/E. In the last year, the stock showed a variation of 102.35 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 102.35%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Apellis Pharmaceuticals (APLS) stock?

Investing in stocks of Apellis Pharmaceuticals (APLS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Apellis Pharmaceuticals (APLS) yield today?

The yield of Apellis Pharmaceuticals (APLS) was 100.55% in the last month, 102.35% in the last year and -2.46% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Apellis Pharmaceuticals (APLS) today, the total investment would be $ 4,041.00, based on the current price of $ 40.41.If past performance were to repeat, the return on your investment would be:In 1 year: $ 8,176.96In 5 years: $ 3,941.59In 10 years: $ 4,041.00It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Apellis Pharmaceuticals Inc.

Price

$ 40.41

return (12m)

102.35%

p/e

229.11

p/bv

13.86

DIVIDEND YIELD

0.00%

APLS price

APLS

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return on Investment APLS

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

100.55%

3 months

56.26%

1 year

102.35%

2 years

-27.90%

5 years

-2.46%

10 years

0.00%

Fundamentals APLS

review the fundamentals of Apellis Pharmaceuticals shares

P/E

229.11

Sector: -5.82 Industry: -5.82

P/S (PSR)

5.11

Sector: -4.74 Industry: -4.74

P/BV

13.86

Sector: 1.40 Industry: 1.40

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

2.08%

Sector: -72.38% Industry: -72.38%

ROE

6.05%

Sector: -84.15% Industry: -84.15%

ROIC

-48.70%

Sector: -1,194.38% Industry: -1,194.38%

NET MARGIN

2.23%

Sector: -46.16% Industry: -46.16%

GROSS MARGIN

89.82%

Sector: 35.92% Industry: 35.92%

OPERATING MARGIN

5.52%

Sector: -46.05% Industry: -46.05%

EV/EBITDA

73.32

Sector: -5.52 Industry: -5.52

EV/EBIT

74.99

Sector: -5.77 Industry: -5.77

PRICE-TO-ASSETS

4.77

Sector: 1.13 Industry: 1.13

BVPS

2.91

Sector: 1.63 Industry: 1.63

EPS

0.18

Sector: -2.73 Industry: -2.73

EQUITY-TO-ASSETS RATIO

0.34

Sector: 0.32 Industry: 0.32

LIABILITIES / ASSETS

0.66

Sector: 0.33 Industry: 0.33

CAGR REVENUE 5 YEARS

75.50%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Apellis Pharmaceuticals ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 40.41

Fair Value

$ 0.00

Upside/Downside Return potential.

-91.50%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals APLS

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	21.84	7.39	33.81%	2.14%	$ 585.48 B	28.46%
PFE	20.72	1.73	8.35%	6.07%	$ 161.03 B	12.42%
ABBV	87.32	0.00	0.00%	3.18%	$ 369.02 B	6.91%
NVO	10.48	5.40	51.50%	4.56%	$ 164.23 B	33.05%
MRK	16.43	0.00	0.00%	2.71%	$ 300.00 B	28.08%
AZN	30.87	6.48	20.99%	1.57%	$ 315.61 B	17.41%
GILD	20.39	7.67	37.62%	2.28%	$ 173.52 B	28.90%
BMY	17.20	-3.56	-20.72%	4.18%	$ 121.35 B	14.64%
ZTS	19.33	15.51	80.25%	1.72%	$ 51.66 B	28.23%
REGN	17.42	2.51	14.41%	0.47%	$ 78.47 B	31.41%
HALO	24.01	155.91	649.21%	0.00%	$ 7.61 B	22.69%
AMGN	24.32	21.66	89.06%	2.78%	$ 187.54 B	20.98%
MCK	25.06	-1,098.65	-4,383.84%	0.36%	$ 108.77 B	1.09%
VRTX	28.19	5.97	21.18%	0.00%	$ 111.43 B	32.94%
CAH	30.39	-18.71	-61.56%	0.95%	$ 50.52 B	0.68%
ADMA	14.89	4.58	30.78%	0.00%	$ 2.19 B	28.80%
BIIB	20.16	1.43	7.08%	0.00%	$ 26.07 B	13.07%
HRMY	9.96	1.82	18.24%	0.00%	$ 1.58 B	18.27%

Stock vs Indice Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

APLS Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

Average Investor10 user rating

4.0 (1 people)

United States

17 years

Founded: 2009

2017

Time since IPO - 9 years

374

Employees

The Company Apellis Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market value of $ 5.13 Billions, having an equity of $ 370.15 Millions.

With a total of 374 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 1.00 Billion, which generated a loss in the amount of $ 22.40 Millions.

As for its main indicators, the Company has a P/E ratio of 229.11, a P/BV ratio of 13.86 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker APLS.

Market cap

$ 5.13 Billions

Net worth

$ 370.15 Millions

US$ 370,150,000.00

Assets

$ 1.08 Billion

US$ 1,075,260,000.00

Total Shares Outstanding

127.00 Millions

127,000,000

Average Daily Trading Volume

$ 5.15 Millions

US$ 5,152,913.34

Sector

Health Care

Industry

Biotechnology

APLS

APLS revenue and profits

Financial Results APLS

DRAG THE FRAME TO SEE MORE DATA

APLS cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 884.28 29,96% (12M)

P/E

25.06

0.36%

ROE

-4,383.84%

P/BV

-1,098.65

CAH - Cardinal Health

$ 214.05 67,60% (12M)

P/E

30.39

0.95%

ROE

-61.56%

P/BV

-18.71

JNJ - Johnson & Johnson

$ 243.04 63,02% (12M)

P/E

21.84

2.14%

ROE

33.81%

P/BV

7.39

PFE - Pfizer

$ 28.32 32,24% (12M)

P/E

20.72

6.07%

ROE

8.35%

P/BV

1.73

ABBV - AbbVie

$ 208.84 16,32% (12M)

P/E

87.32

3.18%

ROE

0.00%

P/BV

0.00

MRK - Merck & Co.

$ 120.87 55,08% (12M)

P/E

16.43

2.71%

ROE

0.00%

P/BV

0.00

AZN - AstraZeneca

$ 203.49 57,42% (12M)

P/E

30.87

1.57%

ROE

20.99%

P/BV

6.48

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 884.28 29,96% (12 M)

P/L

25.06

0.36%

ROE

-4,383.84%

P/VP

-1,098.65

CAH - Cardinal Health

$ 214.05 67,60% (12 M)

P/L

30.39

0.95%

ROE

-61.56%

P/VP

-18.71

JNJ - Johnson & Johnson

$ 243.04 63,02% (12 M)

P/L

21.84

2.14%

ROE

33.81%

P/VP

7.39

PFE - Pfizer

$ 28.32 32,24% (12 M)

P/L

20.72

6.07%

ROE

8.35%

P/VP

1.73

ABBV - AbbVie

$ 208.84 16,32% (12 M)

P/L

87.32

3.18%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 120.87 55,08% (12 M)

P/L

16.43

2.71%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 203.49 57,42% (12 M)

P/L

30.87

1.57%

ROE

20.99%

P/VP

6.48

Frequently Asked Questions

What is the price of Apellis Pharmaceuticals (APLS) today?

The price of Apellis Pharmaceuticals (APLS) today is $ 40.41, with return of 102.35% compared to the last year. The price of Apellis Pharmaceuticals (APLS) started the year trading around $ 25.12 and today it is at $ 40.41. Follow the real-time price chart, the historical price of Apellis Pharmaceuticals (APLS) and international markets.

When does Apellis Pharmaceuticals (APLS) pay dividends?

Apellis Pharmaceuticals (APLS) did not distribute dividends in the last year.

Is Apellis Pharmaceuticals (APLS) worth it?

Currently, Apellis Pharmaceuticals (APLS) is priced at $ 40.41, with a P/E of 229.11%, representing a deviation of 4,662% from its historical average P/E. In the last year, the stock showed a variation of 102.35 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 102.35%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Apellis Pharmaceuticals (APLS) stock?

Investing in stocks of Apellis Pharmaceuticals (APLS) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Apellis Pharmaceuticals (APLS) yield today?

The yield of Apellis Pharmaceuticals (APLS) was 100.55% in the last month, 102.35% in the last year and -2.46% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Apellis Pharmaceuticals (APLS) today, the total investment would be $ 4,041.00, based on the current price of $ 40.41.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 8,176.96
In 5 years: $ 3,941.59
In 10 years: $ 4,041.00

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

APLS

Apellis Pharmaceuticals Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment APLS

review the fundamentals of Apellis Pharmaceuticals shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Apellis Pharmaceuticals

Apellis Pharmaceuticals Inc.

United States

17 years

2017

374

PROFIT X PRICE APLS

Financial Results APLS

APLS cash flow

Asset, Revenue and Profit Growth - APLS

APLS balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions